Make Informed Investment Decisions with Affordable Access to Experts
Discussing the Phase 3 Tenapanor results in Hyperphosphatemia for patients with CKD on dialysis.Ticker(s): ARDX, KERX
Name: Dr Kamyar Kalantar-Zadeh - MD
Institution: UC Irvine
- Chief, Division of Nephrology, Hypertension and Kidney Transplantation at UC Irvine.
- Known for his hypothesis about the longevity of individuals with chronic kidney disease states, also known as reverse epidemiology including obesity paradox.
- Specializes in kidney dialysis therapy, including incremental dialysis, and renal nutrition.
Please describe your clinical practice and how many patients with Hyperphosphatemia you see monthly.Added By: joe_mccann
How do you currently manage these patients?Added By: joe_mccann
Does the mechanism of action for Tenapanor appeal to you? What are the current short coming of the phosphate binders.Added By: joe_mccann
Looking at the top-line results in this press release what are your views on the efficacy seen?Added By: joe_mccann
Turning to side effects, can you put the discontinuation rate of 7.8% for GI issues for the Tenapanor group in context for us? What do you make of that number?Added By: joe_mccann
How much switching due to tolerability do you currently see in this patient population? What other reasons do patients switch or discontinue a treatment.Added By: joe_mccann
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.